The influence of food on itraconazole pharmacokinetics was evaluated for 27 healthy male volunteers in a single-dose (200 mg) crossover study with capsules containing itraconazole-coated sugar spheres. This study was followed by a study of the steady-state pharmacokinetics for the same subjects with 15 days of administration of itraconazole at 200 mg every 12 h. Concentrations of itraconazole and hydroxyitraconazole, the active main metabolite, were measured in plasma by high-performance liquid chromatography. The results of the food interaction segment showed that a meal significantly enhances the amount of itraconazole absorbed. The mean maximum concentration in plasma of unmetabolized itraconazole after fasting (140 ng/ml) was about 59%o that after the standard meal (239 ng/ml). The rate of elimination was not affected (terminal half-life, approximately 21 h). The mean maximum concentration in plasma of hydroxyitraconazole after fasting was about 72% the postmeal concentration (287 and 397 ng/ml, respectively). The terminal half-life of hydroxyitraconazole was approximately 12 h. Steady-state concentrations of itraconazole and hydroxyitraconazole were reached after 14 or 15 days of daily dosing. The average steady-state concentrations were approximately 1,900 ng/ml for itraconazole and 3,200 ng/ml for hydroxyitraconazole. The shape of the elimination curve for itraconazole after the last dose was indicative of saturable elimination. This conclusion was confirmed by the sevenfold increase in the area under the curve from 0 to 12 h at steady state compared with the area under the curve from 0 h to infinity after a single dose. It was furthermore confirmed by the larger-than-expected number of half-lives required to achieve steady-state plasma drug levels.
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Itraconazole is a broad-spectrum antifungal compound that, like other azole antifungal agents, selectively disrupts cytochrome P-450-mediated sterol synthesis in fungal membranes, thereby leading to cell death (1) . It has been studied extensively for a variety of dermatomycoses, vaginal candidiasis, and systemic mycoses, such as histoplasmosis, blastomycosis, and aspergillosis, as well as for the prophylaxis of fungal infections in immunocompromised patients (2, 5, 10) . Currently, doses of 200 mg daily and 200 mg twice daily are used therapeutically.
Experiments with small numbers of subjects indicated that the extent of itraconazole absorption from solid-dose forms is enhanced by administration with food (11) . In that study, polyethylene glycol-formulated capsules were used, but the currently marketed formulation of itraconazole is capsules containing itraconazole-coated sugar spheres.
The present study was undertaken with a large number of subjects to assess the effects of food on itraconazole bioavailability by use of capsules containing itraconazolecoated sugar spheres, the currently marketed formulation. A Subjects were admitted to the study site the evening prior to dosing and were fed dinner. Following dinner, no additional food intake was allowed until the fast was broken as per protocol. Subjects assigned to receive the drug with food were given the drug immediately after a standard breakfast, which consisted of orange juice, egg, bacon, toast with butter and jam, whole milk, and fresh banana. Two 100-mg itraconazole capsules were administered as a single dose with 200 ml of water. No beverage was allowed for 2 h after dosing, and no food was allowed for 4 h. Ten-milliliter blood samples were collected in heparinized tubes immediately predose (time zero) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, and 72 h postdose. The subjects remained at the study site through the 24-h blood sampling and returned for subsequent sampling. After a 2-week washout interval, subjects who had taken itraconazole after fasting were crossed over to take the capsules after a standard meal, and vice versa, and the procedure was repeated.
The drug-food interaction segment of the study was followed by a multiple-dose segment. Starting after the 72-h blood sampling at the end of the second phase of the food interaction segment, each subject was administered two 100-mg itraconazole capsules every 12 h for 14 days. All doses were taken with 200 ml of water following a meal at the study site. During this segment, trough blood samples were obtained prior to morning doses on days 4, 7, 10, 13, and 14. On the evening of day 14, the subjects were admitted to the study site and were fed dinner. A single 200-mg dose was given on the morning of day 15 after breakfast. On day 15, samples were taken predose (time zero) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96 (4 days), 168 (7 days), 240 (10 days), and 360 (15 days) h postdose. The subjects were allowed to leave the study site after the 24-h blood sampling and returned for subsequent blood sampling.
HPLC. Each blood sample was centrifuged within 1 h after sampling. Plasma was separated and stored at < -20'C. The frozen plasma samples were sent to Janssen Research Foundation, where they were analyzed by reverse-phase highperformance liquid chromatography (HPLC) for concentrations of itraconazole (detection limit, 5 ng/ml) and its active main metabolite, hydroxyitraconazole (detection limit, 10 ng/ml). The HPLC method was based in principle on the method of Woestenborghs et al. (13) , except for the addition of hydroxyitraconazole as the second standard and an increase in the polarity of the extraction solvent. where Vm. is the maximal rate of decrease in the concentration in plasma and Km is the concentration at which the rate of decrease is one-half the maximal rate. Vmax/Km is the apparent first-order rate constant for terminal first-order elimination when levels in plasma are much lower than the Km.
Estimates of the Vm, and Km of itraconazole were obtained by regression methods with pairs of concentrations in plasma at their respective times in the elimination phase after the last dose, as described by Garrett and Roth (4).
Statistical analysis. SAS version 5.16 was used for all data manipulation and statistical analyses. The sequences were comparable for age, race, weight, height, blood pressure, pulse, and respiration, as determined by a one-way analysis of variance for continuous variables and the chi-square test for categorical variables. The pharmacokinetic data from the food interaction segment were analyzed by use of an analysis-of-variance model appropriate for the two-period, twotreatment crossover design (6) . The model included effects due to sequences, subjects within sequences, phase, and drug. For Cmn, AUCO-72, and AUCO, analyses were repeated after the data were transformed by use of natural logs. Type III sums of squares were used, and all tests were two sided. The posterior power of the test of drug effects was based on the detection of a 20% or greater difference between the test mean (after fasting) and the reference mean (after a standard breakfast) with testing at alpha = 0.05 (two tailed).
For determination of the bioequivalence of itraconazole capsules taken after fasting or after a standard breakfast, 90% confidence intervals were computed for the bioavailability parameters by use of least-squares means. The 90% confidence intervals were operationally equivalent to the two one-sided tests approach proposed by Shiurman (9) . If the 90% confidence interval for the test treatment fell completely within 80 to 120% that for the reference treatment, the two dosing conditions were declared bioequivalent with respect to the parameter tested. RESULTS All subjects completed the study except one, who was withdrawn after phase 1 of the food interaction segment because the baseline urine drug profile proved positive.
None of the data for this subject were included in the analysis. One subject experienced flatulence and two subjects experienced rash during the food interaction segment.
Food interaction pharmacokinetics. The plasma drug concentration-time curves are shown in Fig. 1 for itraconazole and Fig. 2 for hydroxyitraconazole. Table 1 summarizes the pharmacokinetic parameters and results of the statistical analyses for the food interaction segment (fasting versus fed). The reference treatment was dosing after a standard breakfast. Since the results for the loge-transformed data and the untransformed data were similar, only the results for the untransformed data are presented.
For both unchanged itraconazole and the metabolite hydroxyitraconazole, dosing after a meal produced higher levels in plasma than dosing after fasting, so that the two treatments were not bioequivalent with regard to AUCO72, AUCO_, and Cm. (Table 1 ). The mean peak concentration in plasma of itraconazole for postfast dosing was about 59% that for postmeal dosing (140 versus 239 ng/ml). For hydroxyitraconazole, the proportion was 72% (287 versus 397 ng/ml).
The AUCO, of itraconazole for postfast dosing was about 61% that for postmeal dosing. The AUC_, of hydroxyitraconazole for postfast dosing was on average 65% that for postmeal dosing. The differences in Tma, were at the borderline of statistical significance (Table 1) Table 2 . The pharmacokinetic parameters of itraconazole and hydroxyitraconazole after the last dose are summarized in Table 3 .
Trough concentrations in plasma of itraconazole did not further increase between day 14 and day 15 ( Fig. 3 and Table   2 ), a result indicating that a steady state was attained at day 14. A steady state for hydroxyitraconazole was attained at day 14 (Fig. 4 and Table 2 ). Average steady-state concentrations in plasma were 1,881 + 448 ng/ml for itraconazole and 3,214 + 704 ng/ml for hydroxyitraconazole. The ratios of the AUCO12 at steady state to the AUC,,oo after a single dose were 7.3 + 2.7 for itraconazole and 5.4 + 2.0 for hydroxyitraconazole.
The elimination of itraconazole at steady state was well characterized by Michaelis-Menten kinetics (Fig. 5) ng. h/ml. The apparent first-order half-life at levels in plasma below the Km was 24 12 h.
DISCUSSION
The results of the food interaction segment of this study show that the administration of the currently marketed itraconazole capsule formulation after a meal enhances its absorption into the bloodstream. In the study by Van Peer et al. (11) , the bioavailability of polyethylene glycol-formulated itraconazole capsules taken in the fasting state was on the order of 40% relative to the bioavailability after intake with food. The present study, in which the currently marketed pellet formulation and a larger study population were used, demonstrated absorption after fasting to be about 60% that after a meal. No substantial difference in the rate of absorption was found in either study; only the amount of drug absorbed was affected. Itraconazole is very lipophilic and is almost insoluble in water. The presence of food may increase the solubility of itraconazole, thereby increasing its systemic absorption. Although the decrease in peak levels in plasma under fasting conditions was smaller for hydroxyitraconazole than for itraconazole, the mean hydroxyitraconazole/itraconazole AUC ratios were similar under fasting and fed conditions (i.e., 2.3 and 2.5, respectively). Thus, the extent of hydroxyitraconazole formation was not affected by the presence of food.
In general, the single-dose and steady-state concentrations in plasma obtained in our study are in accord with the values reported by Hardin et al. after the same dosage regimen with five healthy male subjects (7). The steady state of itraconazole was reached after 14 days of dosing in our study, in agreement with the 13 days observed by Hardin et al. (7) . This length of time is longer than the theoretical 4 to 5 days 
